RxDoctor Payments Data

Steven Nguyen, MD

Family Medicine · Houston, TXNPI 1255594180

Payments from drug & device makers

$7,419in general payments, 2019–2025

Across 339 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Gilead$817
  • Novo Nordisk$777
  • Amarin Pharma, Inc.$543
  • GSK$484
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$7,32799%
  • Education$921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,419 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$31,988
Medicare patients
45
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl223$216,118
JardianceEmpagliflozin98$165,145
OzempicSemaglutide51$99,001
FarxigaDapagliflozin Propanediol39$60,207
MyrbetriqMirabegron36$47,316
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$38,129
JanumetSitagliptin Phos/Metformin Hcl19$31,051
EliquisApixaban16$27,253
Celecoxib104$15,758
RestasisCyclosporine24$13,399
Omega-3 Acid Ethyl Esters95$11,312
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,626
Ursodiol21$5,527
Icosapent Ethyl15$4,522
Breo ElliptaFluticasone/Vilanterol11$3,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,019$165,14598 claims
Novo NordiskOzempic$777$99,00151 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,768$67,83251 claims
Astellas Pharma US IncMyrbetriq$72$47,31636 claims
GSKTrelegy Ellipta, Breo Ellipta$484$42,02270 claims
PfizerEliquis$14$27,25316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →